Search Results - "Ribera, J.M."

Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group by Nomdedéu, J, Hoyos, M, Carricondo, M, Esteve, J, Bussaglia, E, Estivill, C, Ribera, J.M, Duarte, R, Salamero, O, Gallardo, D, Pedro, C, Aventin, A, Brunet, S, Sierra, J

“…Abstract The study of genetic lesions in AML cells is helpful to define the prognosis of patients with this disease. This study analyzed the frequency and…”
Get full text

90 INTENSIVE CHEMOTHERAPY VERSUS NO INTENSIVE TREATMENT IN HIGH RISK MYELODYSPLASTYC SYNDROME (MDS) NO-HSCT CANDIDATES by Bargay, J, Xicoy, B, Brunet, S, Tormo, M, Pedro, C, Coll, R, Talarn, C, Marti, J.M, Nomdedeu, M, Font, X, Sampol, A, Borrás, J, Valcárcel, D, Ribera, J.M, Sierra, J

Get full text

A systematic review of surveys on undergraduate teaching of Geriatrics in medical schools in the XXI century by Mateos-Nozal, J, Cruz-Jentoft, A.J, Ribera Casado, J.M

“…Abstract Background Due to population aging, different international organizations recommend that all medical students should receive training in geriatric…”
Get full text

Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size by Nomdedeu, J, Bussaglia, E, Villamor, N, Martinez, C, Esteve, J, Tormo, M, Estivill, C, Queipo, M.P, Guardia, R, Carricondo, M, Hoyos, M, Llorente, A, Juncà, J, Gallart, M, Domingo, A, Bargay, J, Mascaró, M, Moraleda, J.M, Florensa, L, Ribera, J.M, Gallardo, D, Brunet, S, Aventin, A, Sierra, J

“…Abstract NPM mutations are the most common genetic abnormalities found in non-promyelocytic AML. NPM-positive patients usually show a normal karyotype, a…”
Get full text

P-275 Outcome of high-risk myelodysplastic syndrome and secondary acute leukemia treatment in patients below 75 years: CETLAM SMD-09 protocol results by Bargay, J, Xicoy, B, Brunet, S, Tormo, M, Esteve, J, Pedro, C, Martí, J.M, Talarn, C, Ortin, X, Borras, J.B, Guardia, R, Valcárcel, D, Rámila, E, Sampol, A, Ribera, J.M, Sierra, J

Get full text

BAALC -associated miR-3151 is an Independent Prognostic Factor in Young Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia by Díaz-Beyá, M, Navarro, A, Pratcorona, M, Brunet, S, Nomdedéu, J, Ribera, J.M, Tormo, M, Duarte, R, Salamero, O, Gallardo, D, Escoda, L, Nomdedeu, M, Risueño, R.M, Cervantes, F, Sierra, J, Monzó, M, Esteve, J

Get full text

Postural stability in the elderly: Fallers versus non-fallers by Lázaro, M, González, A, Latorre, G, Fernández, C, Ribera, J.M

“…Abstract Objectives (1) To compare static and dynamic balance alterations in recurrent fallers and non-fallers elderly patients. (2) To assess the functional…”
Get full text

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Hoelzer, D, Bassan, R, Dombret, H, Fielding, A, Ribera, J M, Buske, C

Get full text

Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients by Perea, G., Domingo, A., Villamor, N., Palacios, C., Juncà, J., Torres, P., Llorente, A., Fernández, C., Tormo, M., Queipo de Llano, M.P., Bargay, J., Gallart, M., Florensa, L., Vivancos, P., Martí, J.M., Font, Ll, Berlanga, J., Esteve, J., Bueno, J., Ribera, J.M., Brunet, S., Sierra, J., Nomdedéu, J.F.

“…A consecutive series of acute myeloid leukemias (AML) patients was analyzed in conditions which reduce the inter-assay variations (the same flow cytometer, the…”
Get full text

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia by Hoelzer, D, Bassan, R, Boissel, N, Roddie, C, Ribera, J M, Jerkeman, M

Get more information

The history of geriatric medicine. The present: Problems and opportunities by Ribera Casado, J.M

“…Abstract Geriatric medicine has contributed to the advance of medicine by bringing into several basic principles, most of them consolidated nowadays as…”
Get full text

Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT by Ruggeri, A, Sanz, G, Bittencourt, H, Sanz, J, Rambaldi, A, Volt, F, Yakoub-Agha, I, Ribera, J M, Mannone, L, Sierra, J, Mohty, M, Solano, C, Nabhan, S, Arcese, W, Gluckman, E, Labopin, M, Rocha, V

“…We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients…”
Get full text

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 by Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O G, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A K, Foà, R, Gökbuget, N, Goldstone, A H, Goulden, N, Henze, G, Hoelzer, D, Janka-Schaub, G E, Macintyre, E A, Pieters, R, Rambaldi, A, Ribera, J-M, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, van Dongen, J J M

“…Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia…”
Get full text

The clinical dilemma of grade 3 follicular lymphoma by Sorigue, M., Ribera, J.M., Sancho, J.M.

“…The recommended treatment of grade 3 (or grade 3B) follicular lymphoma patients is that of diffuse large B-cell lymphoma rather than that of follicular…”
Get full text

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk by Spina, M., Nagy, Z., Ribera, J.M., Federico, M., Aurer, I., Jordan, K., Borsaru, G., Pristupa, A.S., Bosi, A., Grosicki, S., Glushko, N.L., Ristic, D., Jakucs, J., Montesinos, P., Mayer, J., Rego, E.M., Baldini, S., Scartoni, S., Capriati, A., Maggi, C.A., Simonelli, C.

“…Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. We sought to…”
Get full text

Effectiveness of a follow-up program for elderly heart failure patients after hospital discharge. A randomized controlled trial by González-Guerrero, J.L, Alonso-Fernández, T, García-Mayolín, N, Gusi, N, Ribera-Casado, J.M

“…Abstract Purpose Management programs for high-risk heart failure (HF) patients reduce admission rates, improve quality of life and survival, and lower costs…”
Get full text

Elder abuse in Finland, France, Spain and United Kingdom by Crome, P, Moulias, R, Sánchez-Castellano, C, Tilvis, R, Arora, A, Busby, F, Ribera Casado, J.M, Cruz-Jentoft, A.J

“…Abstract The subject of abuse and the related issues of dignity, poor quality of care and human rights are the most important issue facing health and social…”
Get full text

O-030: Geriatric teaching in Spanish Medical Schools after the implementation of the European higher education area by Mateos-Nozal, J, García Cabrera, L, Montero-Errasquín, B, Lázaro del Nogal, M, Cruz-Jentoft, A.J, Ribera Casado, J.M

Get full text

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma by Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., Camós, M., Colomo, L., Espinosa, Í., Martínez, S., Ribera, J.M., Martino, R., Gutiérrez-García, G., Montserrat, E., López-Guillermo, A.

“…Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young…”
Get full text

MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia by Díaz-Beyá, M, Brunet, S, Nomdedéu, J, Tejero, R, Díaz, T, Pratcorona, M, Tormo, M, Ribera, J M, Escoda, L, Duarte, R, Gallardo, D, Heras, I, Queipo de Llano, M P, Bargay, J, Monzo, M, Sierra, J, Navarro, A, Esteve, J

“…Acute myeloid leukemia (AML) is a heterogeneous disease, and optimal treatment varies according to cytogenetic risk factors and molecular markers. Several…”
Get full text